Last reviewed · How we verify
CKD-841 A-1 1.88mg
At a glance
| Generic name | CKD-841 A-1 1.88mg |
|---|---|
| Also known as | CKD-841 |
| Sponsor | Chong Kun Dang Pharmaceutical |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- The Safety and Pharmacokinetic/Pharmacodynamic Study of CKD-841 in Postmenopausal Female, Phase 1 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CKD-841 A-1 1.88mg CI brief — competitive landscape report
- CKD-841 A-1 1.88mg updates RSS · CI watch RSS
- Chong Kun Dang Pharmaceutical portfolio CI